文献速递消化道肿瘤与早癌消化内镜

粪便梭杆菌定量检测提高粪便免疫化学检测对进展期结直肠肿瘤的检出

Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia.
PubMed 文献 · Gut · 2016-10-24

在309例受试者(104例结直肠癌、103例进展期腺瘤、102例对照)中定量检测粪便具核梭杆菌、厌氧消化链球菌和微小单胞菌,并在181例独立队列中验证。具核梭杆菌联合粪便免疫化学检测(FIT)较单用FIT提高了结直肠癌和进展期腺瘤的敏感性与曲线下面积,验证队列结果一致。

要点

  • 具核梭杆菌(Fn)丰度在结直肠癌患者高于对照(p<0.001),在进展期腺瘤患者高于对照(p=0.022)。
  • Fn联合FIT检测结直肠癌的敏感性为92.3%对73.1%(p<0.001),AUC为0.95对0.86(p<0.001)。
  • Fn联合FIT检测进展期腺瘤的敏感性为38.6%对15.5%(p<0.001),AUC为0.65对0.57(p=0.007)。

核心结论

  • 研究识别出标记物Fn可提高FIT的诊断性能,对FIT单独漏检的病变起补充作用。
  • 作者认为这一简单方法可能提高当前FIT的临床效用,并朝无创、可能更准确且可负担的进展期结直肠肿瘤诊断迈进一步。

研究设计与样本

  • 在309例受试者(104例结直肠癌、103例进展期腺瘤、102例对照)中通过定量PCR检测具核梭杆菌(Fn)、厌氧消化链球菌(Pa)和微小单胞菌(Pm)的相对丰度,评估其相对FIT的诊断性能。
  • 结果在181例受试者的独立队列中验证。

主要发现

  • 三种标记物在结直肠癌患者中的丰度均高于对照(p<0.001),标记物Fn在进展期腺瘤患者中的丰度高于对照(p=0.022)。
  • 在同一患者队列中检测结直肠癌,Fn联合FIT较单用FIT显示更高的敏感性(92.3%对73.1%,p<0.001)和更高的受试者工作特征曲线下面积(AUC)(0.95对0.86,p<0.001)。
  • 检测进展期腺瘤,该联合检测提高了敏感性(38.6%对15.5%,p<0.001)和AUC(0.65对0.57,p=0.007)。
  • 结直肠癌和进展期腺瘤的性能提升在验证队列中得到确认(分别为p=0.0014和p=0.031)。

临床怎么用

  • 原文结论认为标记物Fn可提高FIT的诊断性能,对FIT单独漏检的病变起补充作用。
  • 作者认为这一简单方法可能提高当前FIT的临床效用,并朝无创、可能更准确且可负担的进展期结直肠肿瘤诊断迈进一步。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is a need for an improved biomarker for colorectal cancer (CRC) and advanced adenoma. We evaluated faecal microbial markers for clinical use in detecting CRC and advanced adenoma. DESIGN: We measured relative abundance of Fusobacterium nucleatum (Fn), Peptostreptococcus anaerobius (Pa) and Parvimonas micra (Pm) by quantitative PCR in 309 subjects, including 104 patients with CRC, 103 patients with advanced adenoma and 102 controls. We evaluated the diagnostic performance of these biomarkers with respect to faecal immunochemical test (FIT), and validated the results in an independent cohort of 181 subjects. RESULTS: The abundance was higher for all three individual markers in patients with CRC than controls (p<0.001), and for marker Fn in patients with advanced adenoma than controls (p=0.022). The marker Fn, when combined with FIT, showed superior sensitivity (92.3% vs 73.1%, p<0.001) and area under the receiver-operating characteristic curve (AUC) (0.95 vs 0.86, p<0.001) than stand-alone FIT in detecting CRC in the same patient cohort. This combined test also increased the sensitivity (38.6% vs 15.5%, p<0.001) and AUC (0.65 vs 0.57, p=0.007) for detecting advanced adenoma. The performance gain for both CRC and advanced adenoma was confirmed in the validation cohort (p=0.0014 and p=0.031, respectively). CONCLUSIONS: This study identified marker Fn as a valuable marker to improve diagnostic performance of FIT, providing a complementary role to detect lesions missed by FIT alone. This simple approach may improve the clinical utility of the current FIT, and takes one step further towards a non-invasive, potentially more accurate and affordable diagnosis of advanced colorectal neoplasia.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Wong SH, Kwong TNY, Chow TC, et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut. 2016. PMID: 27797940. doi:10.1136/gutjnl-2016-312766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。